Compare Stocks: ALLO, SLS, NKTR, and AUPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.67	$1.90	$1.04 ▼ $4.46	$590.79M	0.47	5.25 million shs	7.75 million shs
AUPH Aurinia Pharmaceuticals	$16.59 +1.2%	$15.92	$10.34 ▼ $19.25	$2.22B	1.4	779,368 shs	809,209 shs
NKTR Nektar Therapeutics	$59.38 +3.0%	$71.22	$33.40 ▼ $109.00	$2.08B	1.14	929,940 shs	2.41 million shs
SLS SELLAS Life Sciences Group	$11.98 +4.0%	$12.45	$1.39 ▼ $15.88	$2.43B	2.52	6.97 million shs	4.63 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-3.47%	-23.04%	-21.60%	+35.77%
AUPH Aurinia Pharmaceuticals	+1.16%	-2.18%	-0.96%	-3.71%	+28.80%
NKTR Nektar Therapeutics	+2.98%	-13.14%	-20.78%	-6.71%	-1.57%
SLS SELLAS Life Sciences Group	+3.99%	+3.90%	-14.98%	-3.31%	+634.97%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.67	$1.90	$1.04 ▼ $4.46	$590.79M	0.47	5.25 million shs	7.75 million shs
AUPH Aurinia Pharmaceuticals	$16.59 +1.2%	$15.92	$10.34 ▼ $19.25	$2.22B	1.4	779,368 shs	809,209 shs
NKTR Nektar Therapeutics	$59.38 +3.0%	$71.22	$33.40 ▼ $109.00	$2.08B	1.14	929,940 shs	2.41 million shs
SLS SELLAS Life Sciences Group	$11.98 +4.0%	$12.45	$1.39 ▼ $15.88	$2.43B	2.52	6.97 million shs	4.63 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-3.47%	-23.04%	-21.60%	+35.77%
AUPH Aurinia Pharmaceuticals	+1.16%	-2.18%	-0.96%	-3.71%	+28.80%
NKTR Nektar Therapeutics	+2.98%	-13.14%	-20.78%	-6.71%	-1.57%
SLS SELLAS Life Sciences Group	+3.99%	+3.90%	-14.98%	-3.31%	+634.97%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.69	Moderate Buy	$8.30	397.01% Upside
AUPH Aurinia Pharmaceuticals	2.67	Moderate Buy	$17.67	6.49% Upside
NKTR Nektar Therapeutics	2.77	Moderate Buy	$138.50	133.24% Upside
SLS SELLAS Life Sciences Group	2.33	Hold	$10.00	-16.53% Downside

Current Analyst Ratings Breakdown

Latest ALLO, SLS, NKTR, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	NKTR Nektar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$80.00 ➝ $50.00
9/22/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/9/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
8/28/2026	NKTR Nektar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/26/2026	ALLO Allogene Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/24/2026	NKTR Nektar Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	NKTR Nektar Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$65.00
8/20/2026	AUPH Aurinia Pharmaceuticals	Bloom Burton Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	28,848.42	N/A	N/A	$1.30 per share	1.28
AUPH Aurinia Pharmaceuticals	$283.05M	7.80	$1.01 per share	16.45	$4.41 per share	3.76
NKTR Nektar Therapeutics	$55.23M	36.71	N/A	N/A	$4.41 per share	13.46
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	$0.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$190.89M	-$0.67	N/A	N/A	N/A	N/A	-50.04%	-36.74%	11/5/2026 (Estimated)
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	7.24	15.36	N/A	100.84%	26.11%	19.89%	11/3/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
SLS SELLAS Life Sciences Group	-$26.86M	-$0.21	N/A	N/A	N/A	N/A	-35.91%	-33.34%	11/11/2026 (Estimated)

Latest ALLO, SLS, NKTR, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/12/2026	Q2 2026	ALLO Allogene Therapeutics	-$0.1714	-$0.13	+$0.0414	-$0.13	$0.00 million	$4.64 million
8/11/2026	Q2 2026	SLS SELLAS Life Sciences Group	-$0.0450	-$0.05	-$0.0050	-$0.05	N/A	N/A
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	10.72	10.72
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
NKTR Nektar Therapeutics	N/A	10.42	10.42
SLS SELLAS Life Sciences Group	N/A	18.83	18.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
AUPH Aurinia Pharmaceuticals	36.83%
NKTR Nektar Therapeutics	75.88%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
AUPH Aurinia Pharmaceuticals	10.40%
NKTR Nektar Therapeutics	2.50%
SLS SELLAS Life Sciences Group	1.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	152	345.49 million	299.89 million	Optionable
AUPH Aurinia Pharmaceuticals	128	133.05 million	119.21 million	Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable
SLS SELLAS Life Sciences Group	13	201.95 million	199.32 million	Not Optionable

ALLO, SLS, NKTR, and AUPH Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 24 at 5:34 PM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 22 at 8:12 PM | globenewswire.com

SELLAS Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced In

September 21, 2026 | seekingalpha.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down - Should You Sell?

September 17, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 17, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 15, 2026 | globenewswire.com

SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 4.8% - Here's Why

September 11, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 10, 2026 | prnewswire.com

Wellington Management Group LLP Grows Stock Holdings in SELLAS Life Sciences Group, Inc. $SLS

September 9, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 8, 2026 | globenewswire.com

SELLAS Life Sciences Group, Inc. (SLS)

September 4, 2026 | finance.yahoo.com

Bank of New York Mellon Corp Makes New Investment in SELLAS Life Sciences Group, Inc. $SLS

September 4, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 3, 2026 | prnewswire.com

SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data

September 3, 2026 | finance.yahoo.com

Most and least shorted mid- to mega-cap healthcare stocks at the end of August

September 2, 2026 | seekingalpha.com

Sellas gears up to present preclinical SLS009 data for pancreatic cancer at major oncology conference

September 2, 2026 | msn.com

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

September 2, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

September 1, 2026 | globenewswire.com

Why analysts think Sellas Life Sciences stock can gain 150% from here

September 1, 2026 | msn.com

Bank of America Corp DE Acquires 540,748 Shares of SELLAS Life Sciences Group, Inc. $SLS

September 1, 2026 | marketbeat.com

Sellas CEO Stergiou says ‘rigorous, unblinded’ data from pivotal AML trial will 'speak for itself' as REGAL catalyst nears

August 31, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALLO, SLS, NKTR, and AUPH Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.67 0.00 (0.00%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$1.69 +0.02 (+1.26%)

As of 06:50 AM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Aurinia Pharmaceuticals NASDAQ:AUPH

$16.59 +0.19 (+1.16%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$16.49 -0.10 (-0.60%)

As of 09/24/2026 07:30 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Nektar Therapeutics NASDAQ:NKTR

$59.38 +1.72 (+2.98%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$62.14 +2.76 (+4.64%)

As of 06:49 AM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

SELLAS Life Sciences Group NASDAQ:SLS

$11.98 +0.46 (+3.99%)

Closing price 09/24/2026 04:00 PM Eastern

Extended Trading

$11.95 -0.03 (-0.25%)

As of 06:53 AM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLO, SLS, NKTR, and AUPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLO, SLS, NKTR, and AUPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLO, SLS, NKTR, and AUPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALLO, SLS, NKTR, and AUPH Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Aurinia Pharmaceuticals NASDAQ:AUPH

Nektar Therapeutics NASDAQ:NKTR

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALLO, SLS, NKTR, and AUPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALLO, SLS, NKTR, and AUPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALLO, SLS, NKTR, and AUPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALLO, SLS, NKTR, and AUPH Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

Aurinia Pharmaceuticals NASDAQ:AUPH

Nektar Therapeutics NASDAQ:NKTR

SELLAS Life Sciences Group NASDAQ:SLS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools